INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)
SHEET 1 OF 4

	F 10/36/06 Equivalent
Application No.	10/561029
Filing Date	03-16-2007
First Named Inventor	Millar, Douglas Spencer
Art Unit	1637
Examiner	Thomas, David C.
Attorney Docket No.	ALAR9.001APC

U.S. PATENT DOCUMENTS	
-----------------------	--

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,156,501	12-05-2000	McGall et al.	
	2	7,288,373	10-2007	Millar et al.	
	3	7,504,207	03-17-2009	Peter Leonard Bergquist	
	4	2004/0086944	05-2004	Grigg et al.	
	5	2004/0203004	10-2004	Bernard et al.	
	6	2004/0219539	11-04-2004	Millar et al.	
	7	2005/0202490	09-15-2005	Vladimir L. Makarov	
	8	2006/0051771	03-09-2006	Murphy et al.	
	9	2006/0166203	07-27-2006	Nigel Took	
	10	2007/0020633	01-25-2007	Douglas Spencer Millar	
	11	2007/0042365	02-22-2007	Millar et al.	
	12	2007/0178459	08-02-2007	Douglas Spencer Millar	
	13	2007/0190530	08-16-2007	Birkner et al.	
	14	2007/0264653	11-15-2007	Berlin et al.	
	15	2008/0050738	02-28-2008	Douglas Spencer Millar	
	16	2009/0029346	01-29-2009	Millar et al.	
	17	2009/0130657	05-21-2009	Douglas Spencer Millar	
	18	2009/0263909	10-22-2009	Douglas Spencer Millar	

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1 Publication Date MM-DD-YYYY Name of Patentee or Applicant Figures Appear T Pages, Columns, Lines Where Columns, Lines Where T Figures Appear				
	19	DE 103 31 107 B3	12-02-2004	Epigenomics AG		
	20	WO 2004/096825	11-11-2004	Human Genetics Signatures Pty Ltd		
	21	WO 2004/111266	12-23-2004	Human Genetic Signatures Pty. Ltd.		

Applera Corporation

Applied Biosystems Group

Examiner Signature	Date Considered

03-10-2005

WO 2005/021778

22

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T1 - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)
SHEET 2 OF 4

	PTO/SB/08 Equivalen
Application No.	10/561029
Filing Date	03-16-2007
First Named Inventor	Millar, Douglas Spencer
Art Unit	1637
Examiner	Thomas, David C.
Attorney Docket No.	ALAR9.001APC

	FOREIGN PATENT DOCUMENTS					
Examiner Initials			Т1			
	23	WO 2006/058393		Human Genetics Signatures Pty Ltd		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials				
	24	BADAL SUSHMA ET AL: "The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation" VIROLOGY, Vol. 324, No. 2, 1 July 2004 (2004-07-01), pages 483-492.		
	25	BADAL V. ET AL: "CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: Genomic hypomethylation correlates with carcinogenic progression" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, Vol. 77, No. 11, 1 June 2003 (2003-08-01), pages 6227-6234.		
	26	BALERIOLA C et al.: "Comparison of a novel HPV test with the Hybrid Capture II (hcll) and a reference PCR method shows high specificity and positive predictive value for 13 high-risk human papillomavirus infections" Journal Of Clinical Virology, Elsevier, Amsterdam, NL, Vol. 42, No. 1, 1 May 2008 (2008-05-01), pages 22-26.		
	27	Extended European Search Report issued in corresponding European Application No. 05821631.8, dated November 7, 2008.		
	28	FENG ET AL: "Detection of hypermethylated genes in women with and without cervical neoplasia." JOURNAL OF THE NATIONAL CANCER INSTITUTE 16 FEB 2005, Vol. 97, No. 4, 16 February 2005 (2005-02-16), pages 273-282.		
	29	GU W. et al, Depletion of Saccharomyces cerevisiae tRNAHis Guanylyttransferase Thglp leads to uncharged tRNAH is with additional m5C, Mol Cell Biol. 2005 September; Vol. 25, No. 18, pages 8191-8201.		
	30	International Search Report issued in corresponding PCT Application No. PCT/AU2006/000755, dated August 30, 2006.		
	31	International Search Report issued in corresponding PCT application number PCT/AU2004/000083, mailed February 24, 2004.		
	32	International Search Report issued in corresponding PCT application number PCT/AU2004/000549, mailed July 23, 2004.		
	33	International Search Report issued in corresponding PCT application number PCT/AU2004/000722, mailed June 29, 2004.		
	34	International Search Report issued in corresponding PCT application number PCT/AU2004/001196, mailed September 27, 2004.		
	35	International Search Report issued in corresponding PCT application number PCT/AU2005/001374, mailed November 9, 2005.		
	36	International Search Report issued on corresponding PCT Application No. PCT/AU2008/000367, dated May 14, 2008.		

Examiner Signature	Date Considered
*Evernines: Initial if reference considered, whether or not citation is in conferm	cance with MDED 600. Draw line through citation if

not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 3 OF 4

Application No. 10/561029 Filing Date 03-16-2007 First Named Inventor Millar, Douglas Spencer Art Unit 1637 Examiner Thomas, David C. Attorney Docket No. ALAR9.001APC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T¹	
	37	KALANTARI, Mina et al. "Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia," Journal of Virology, Vol. 78, No. 23, December 2004, pages 12762-12772.		
	38	KIM T Y ET AL: "DNA hypermethylation in gastric cancer" ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 20, No. Suppl. 1, July 2004 (2004-07), pages 131-142.		
	39	CELL, Vol. 19, 1980, pages 79 - 90.		
	40	MALYUKOVA A V ET AL: "Methylation of the Putative Tumor Suppressor Gene RASSF1A in Primary Cervical Tumors" MOLECULAR BIOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, Vol. 38, No. 6, 1 November 2004 (2004-11-01), pages 857-864.		
	41	NARAYAN, Gopeshwar et al: "Frequent Promoter Methylation of CDH1, DAPK, RARB, and HIC1 Genes in Carcinoma of Cervix Uteri: Its Relationship to Clinical Outcome" Molecular Cancer, Biomed Central, London, GB, Vol. 2, No. 1, 13 May 2003 (2003-05-13), page 24.		
	42	NOUSBAUM, J. et al., "Prospective Characteristics of Full-Length Hepatitis C Virus NS5A Quasispecies during induction and Combination Antiviral Therapy," Journal of Virology, 74, No.19, pages 9028-9038 (2000).		
	43	Office Action in U.S. Application No. 10/543,017 dated August 8, 2007. Our Ref. ALAR18.001APC		
	44	Office Action in U.S. Application No. 10/543,017 dated December 8, 2008, Our Ref. ALAR18.001APC		
	45	Office Action in U.S. Application No. 10/543,017 dated June 20, 2008, Our Ref. ALAR18.001APC		
	46	Office Action in U.S. Application No. 10/543,017 dated October 19, 2007, Our Ref. ALAR18.001APC		
	47	Office Action in U.S. Application No. 10/570,715 dated December 14, 2009. Our Ref. ALAR22.001APC		
	48	Office Action in U.S. Application No. 11/573,873 dated May 4, 2009, Our Ref. ALAR31.001APC		
	49	Office Action in U.S. Application No. 11/573,873 dated September 2, 2009, Our Ref. ALAR31.001APC		
	50	Office Action in U.S. Application No. 11/660,586 dated September 15, 2009, Our Ref. ALAR15.001APC		
	51	RATUSHNA V.G. et al.: "Secondary structure in the target as a confounding factor in synthetic oligomer microarray design," BMC GENOMICS, Vol. 6, No. 1, March 2005, page 31.		
	52	Supplementary European Search Report issued in corresponding European Application No. 05779000.8, dated November 24, 2008.		
	53	Supplementary European Search Report issued on corresponding European Patent Application No. EP 05 81 3335, dated March 12, 2009.		
	54	Supplementary European Search Report issued on corresponding European Patent Application No. EP 06 77 4977, dated July 28, 2009 (ALAR36.001APC).		

Examiner Signature	Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conform	nance with MDED 600	Draw line through citation if	

not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Multiple sheets used when necessary)

SHEET 4 OF 4

	F	PTO/SB/08 Equivalent
Application No.	10/561029	
Filing Date	03-16-2007	
First Named Inventor	Millar, Douglas Spencer	
Art Unit	1637	
Examiner	Thomas, David C.	
Attorney Docket No.	ALAR9.001APC	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials			T ¹
	55	USHIJIMA TOSHIKAZU ET AL: "Aberrant methylations in cancer cells: Where do they come from?" CANCER SCIENCE, Vol. 96, No. 4, April 2005 (2005-04), pages 206-211.	-
	56	VERMA M: "VIRAL GENES AND METHYLATION" ANNALS OF THE NEW YORK ACADEMY OF SCIENCES 200303 US, VOL. 983, MARCH 2003 (2003-03), PAGES 170-180.	
	57	WIDSCHWENDTER et al.: "Analysis Of Aberrant DNA Methylation And Human Papillomavirus DNA In Cervicovaginal Specimens To Detect Invasive Cervical Cancer And Its Precursors" Clinical Cancer Research, The American Association For Cancer Research, US, Vol. 10, No. 10, 15 May 2004 (2004- 05-15), Pages 3398-3400.	
	58	VANAGI ef al., "HEPATITIS C VIRUS: AN INFECTIOUS MOLECULAR CLONE OF A SECOND MAJOR GENOTYPE (2A) AND LACK OF VIABILITY OF INTERTYPIC 1A AND 2A CHIMERAS," VIROLOGY 262, PAGES 250-263 (1999).	
	59	ZESCHNIGK et al., "A novel real-time PCR assay for quantitative analysis of methylated alleles (QAMA): analysis of the retinoblastoma locus," Nucleic Acid Research 2004, Volume 32, No. 16, pages 1-5.	

8741861 041910

Examiner Signature	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.